^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
locnartecan (PEN-866)
i
Other names: HDC SN-38, PEN-866, STA-12-8666, HDC conjugated with SN-38, PEN866, PEN 866, STA-8666, STA 12 8666
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Madrigal Pharma, National Cancer Institute - Bethesda, SciClone, Tarveda Therap
Drug class:
Topoisomerase I inhibitor, HSP90 inhibitor
Related drugs:
2years
PEN-866 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1/2, N=340, Recruiting, Tarveda Therapeutics | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
Trial completion date • Trial primary completion date
|
HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • locnartecan (PEN-866)
almost3years
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=64, Not yet recruiting, National Cancer Institute (NCI)
Clinical • New P1/2 trial • Combination therapy
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
UGT1A1*28 • UGT1A1*1*1
|
temozolomide • vincristine • locnartecan (PEN-866)
Share via
